ResearcherUniversity of North Carolina at CharlotteNo recent work listed
Mahboubeh Yazdanifar
Matched on ORCID iD 0000-0003-1884-3383; OpenAlex author ID A5059702696. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 2 papers
Papers 6
- Controversial role of γδ T cells in pancreatic cancer. First author DOI 10.1016/j.intimp.2022.108895↗
- Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fcell.2022.821875↗
- Tumor -Associated MUC1 Regulates TGF-β Signaling and Function in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.1101/2020.04.29.068577↗
- Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells8091070↗
- Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles. Co-author DOI 10.1186/s12885-018-4393-7↗
- A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis. Co-author DOI 10.1038/onc.2015.516↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ru Zhou · 5 shared papers, 2016–2022 · strength 0.46
- Paper Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma. DOI 10.3389/fcell.2022.821875↗
- Paper Tumor -Associated MUC1 Regulates TGF-β Signaling and Function in Pancreatic Ductal Adenocarcinoma DOI 10.1101/2020.04.29.068577↗
- Paper Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic… DOI 10.3390/cells8091070↗
- Pinku Mukherjee · 5 shared papers, 2016–2022 · strength 0.46
- Paper Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma. DOI 10.3389/fcell.2022.821875↗
- Paper Tumor -Associated MUC1 Regulates TGF-β Signaling and Function in Pancreatic Ductal Adenocarcinoma DOI 10.1101/2020.04.29.068577↗
- Paper Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic… DOI 10.3390/cells8091070↗
- Priyanka Grover · 4 shared papers, 2016–2022 · strength 0.39
- Paper Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma. DOI 10.3389/fcell.2022.821875↗
- Paper Tumor -Associated MUC1 Regulates TGF-β Signaling and Function in Pancreatic Ductal Adenocarcinoma DOI 10.1101/2020.04.29.068577↗
- Paper Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic… DOI 10.3390/cells8091070↗
- Mukulika Bose · 3 shared papers, 2019–2022 · strength 0.34
- Paper Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma. DOI 10.3389/fcell.2022.821875↗
- Paper Tumor -Associated MUC1 Regulates TGF-β Signaling and Function in Pancreatic Ductal Adenocarcinoma DOI 10.1101/2020.04.29.068577↗
- Paper Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic… DOI 10.3390/cells8091070↗
- Shu-ta Wu · 3 shared papers, 2018–2020 · strength 0.27
- Paper Tumor -Associated MUC1 Regulates TGF-β Signaling and Function in Pancreatic Ductal Adenocarcinoma DOI 10.1101/2020.04.29.068577↗
- Paper Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic… DOI 10.3390/cells8091070↗
- Paper Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA n… DOI 10.1186/s12885-018-4393-7↗
- Sritama Nath · 2 shared papers, 2020–2022 · strength 0.25
- Fatemeh Nezhad Shamohammadi · 1 shared paper, 2022 · strength 0.15
- Haideh Namdari · 1 shared paper, 2022 · strength 0.15
- John F. Maher · 1 shared paper, 2019 · strength 0.09
- Didier Dréau · 1 shared paper, 2019 · strength 0.09
- Lopamudra Das Roy · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.